The public record · 119th Congress

Expedited Access to Biosimilars Act

The Congressional Research Service has not published a summary of this measure.

Other titles

the names this measure carries besides the one at the top of this page, each with the record's own label for it. The collection includes titles given to parts of a bill as well as to the whole.

A bill to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.Official Title as Introduced

Expedited Access to Biosimilars ActShort Title(s) as IntroducedShort Title(s) as Reported to Senate

Legislative history

S. 1414·Senate·Bill·Health

Sen. Rand Paul(Republican-Kentucky)·

Apr 10, 2025

SenateRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Jul 22, 2026

Senate · CommitteeCommittee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Jul 27, 2026

Senate · CommitteeCommittee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

Jul 27, 2026

SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 520.

Documents

Everything Congress printed about this measure. A bill is reprinted each time it changes, the Congressional Research Service summarizes each version, and the committee that reports a bill files its own written account of it.

Bill text

Jul 27, 2026As reported by the Senate committee Apr 10, 2025As introduced in the Senate